2020
Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
Marczyk M, Patwardhan GA, Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells. Cancers 2020, 12: 2551. PMID: 32911681, PMCID: PMC7563413, DOI: 10.3390/cancers12092551.Peer-Reviewed Original ResearchTriple-negative breast cancer cellsCancer cellsBreast cancer cellsStress response genesMulti-omics landscapeCell population compositionDrug-induced cell deathMulti-omics investigationsCell linesBCL2 family inhibitorsSingle-cell analysisChromatin accessibilityGenome structureMDA-MB-231 triple-negative breast cancer cellsChromatin structureMethylation stateResponse genesFamily inhibitorsCell deathTNBC cell linesNumber variationsDefense mechanismsResistance mechanismsNew therapeutic strategiesGenes
2017
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clinical Cancer Research 2017, 23: 1710-1721. PMID: 27702820, PMCID: PMC5378660, DOI: 10.1158/1078-0432.ccr-15-2851.Peer-Reviewed Original ResearchConceptsCancer-associated fibroblastsBreast cancer cellsBreast cancerER expressionPatient outcomesCancer cellsEstrogen receptor-positive breast cancerReceptor-positive breast cancerTamoxifen-resistant breast cancer cellsBreast cancer-associated fibroblastsInferior clinical responseMajor clinical complicationsER expression levelsEstrogen-dependent proliferationWorse patient outcomesClin Cancer ResPatient breast tumorsTumor cell sensitivityTumor cell resistanceAntiendocrine therapyTamoxifen therapyClinical responseDisease recurrenceClinical complicationsDevelopment of resistance